多肿瘤标志物蛋白芯片检测系统在肺癌诊断中的临床意义

Clinical value of multi-tumor markers protein biochip in the diagnosis of pulmonary carcinoma

目的探讨多肿瘤标志物蛋白芯片检测在肺癌诊疗中的应用价值。方法采用蛋白芯片技术检测肺癌患者308例、肺部良性病变患者218例、健康体检者250例血清中的12种肿瘤标志物(CA199、NSE、CEA、CA242、Ferrtin、β-HCG、AFP、f-PSA、PSA、CA125、HGH、CA153)水平。结果肺癌组阳性率为72.4%,显著高于良性病变组的22.0%和健康对照组的5.6%(P<0.01);不同病理类型的肺癌患者阳性率存在差异,腺癌中CEA、CA125、CA153的阳性率和含量明显高于鳞癌(P<0.05),有淋巴结转移组的阳性率71.9%,明显高于无淋巴结转移组的52.1%(P<0.05)。结论多肿瘤标志物蛋白芯片检测系统对肺癌的辅助诊断和疗效监测有较高的临床价值。

Objective To assess the value of multi-tumor markers protein biochip in the diagnosis and therapy of pulmonary carcinoma.Methods Twelve tumor markers（CA199,NSE,CEA,CA242,Ferrtin,β-HCG,AFP,f-PSA,PSA,CA125,HGH,and CA153） were detected using protein chip in 308 patients with pulmonary carcinoma,218 with benign lung lesions and 250 healthy subjects.Results The positivity rate was 72.4% in pulmonary carcinoma cases,obviously higher than that in the benign cases（22.0%,P〈0.01） and healthy subjects（5.6%,P〈0.01）.The positivity rates differed significantly between the pulmonary carcinoma cases of different pathological types.The positivity rates of CEA,CA125,and CA153 were significantly higher in adenocarcinoma cases than in squamous carcinoma cases（P〈0.05）,and also higher in cases with lymph node metastasis than in those without（71.9% vs 52.1%,P〈0.05）.Conclusion Protein biochip containing multiple tumor markers provides valuable assistance in the diagnosis and therapeutic effect monitoring of pulmonary carcinoma.